Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, MD, Catherine S Diefenbach, MD, Nehal Lakhani, MD PhD, Sarah C Rutherford, MD, Marshall T Schreeder, MD, Stephen M Ansell, MD PhD, Taimur Sher, MD, David M Aboulafia, MD, Jonathon B Cohen, MDMS, Darrell Nix, BS, PhD, Sean Landrette, PhD, Kate Flanders, BS, Langdon L Miller, MD, Henri Lichenstein, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017) 130 (Supplement 1): 4119.

https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119

Published: 2017

Journal Articles

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Kevin A David, MD, Jonathon Cohen, Michael Robertson, MD, Ranjana Advani, MD, Neil D. Palmisiano, MD, Richard F. Ambinder, MD PhD, Brad S Kahl, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 1106.

https://doi.org/10.1182/blood.V128.22.1106.1106

Published: 2016

Journal Articles

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Jonathon B. Cohen, MD, Michael J. Robertson, MD, Richard F. Ambinder, MD PhD, Timothy S. Fenske, MD, Ranjana H Advani, MD, Brad S Kahl, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 585.

https://doi.org/10.1182/blood.V126.23.585.585

Published: 2015

Journal Articles

Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Catherine S. Diefenbach, MD, David J. Valacer, MD, Jack Higgins, PhD, Michelle A. Fanale

Blood (2015) 126 (23): 5112.

https://doi.org/10.1182/blood.V126.23.5112.5112

Published: 2015

Journal Articles

Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation

Catherine S. Diefenbach, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Tibor Moskovits, MD, David Kaminetzky, MD, Peter Martin, MD, Jia Ruan, MD PhD, Stephanie Lauro, RN, BSN, CCRC, Danielle Banks, CCRP, Krysten Brown, MA, Maryam Bonakdar, Cem Abidoglu, Lina Kozhaya, John P. Leonard, MD, Derya Unutmaz, MD

Blood (2014) 124 (21): 4400.

https://doi.org/10.1182/blood.V124.21.4400.4400

Published: 2014

Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood (2014) 124 (21): 4457.

https://doi.org/10.1182/blood.V124.21.4457.4457

Published: 2014

Journal Articles

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Blood (2013) 122 (21): 4277.

https://doi.org/10.1182/blood.V122.21.4277.4277

Published: 2013

Journal Articles

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Catherine S. Diefenbach, MD, David Kaminetzky, MD, Shannon Andersen, MSN, NP, Jane Chin, NP, Barbara MacGregor-Cortelli, BSN, RN, OCN, Jasmine M Zain, MD

Blood (2012) 120 (21): 4863.

https://doi.org/10.1182/blood.V120.21.4863.4863

Published: 2012

Journal Articles

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Christopher L. Brooks, PhD, Jairo Baquero-Buitrago, MSc, Crystal Cruz, Isabelita Vengco, Francesca Montanari, MD, Enrica Marchi, MD, Ph.D., Luigi Scotto, Ph.D., Thomas P. Cirrito, PhD, Ivan Bergstein, MD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3737.

https://doi.org/10.1182/blood.V118.21.3737.3737

Published: 2011

Journal Articles

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,

Jasmine M. Zain, MD, Francine M. Foss, MD, Catherine S. Diefenbach, MD, Daniel Petrylak, MD, Ameet Narwal, Ellen Neylon, NP, RN, BSN, OCN, Poul Knoblauch, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3710.

https://doi.org/10.1182/blood.V118.21.3710.3710

Published: 2011

Journal Articles

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Sean Clark-Garvey, Crystal Cruz, Isabelita Vengco, Celeste N Rojas, Victoria Serrano, MPH, Jasmine M. Zain, MD, Hearn J. Cho, MD, PhD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 4860.

https://doi.org/10.1182/blood.V118.21.4860.4860

Published: 2011

Journal Articles

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.

Jasmine M. Zain, MD, Francine M Foss, MD, Johann S. de Bono, Ameet Narwal, Ellen Neylon, RN, BSN, OCN, George Blumenschein, U. Lassen, MD, Poul Knoblauch, Catherine S. Diefenbach, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 1787.

https://doi.org/10.1182/blood.V116.21.1787.1787

Published: 2010

Journal Articles

Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

Francesca Montanari, MD, Govind Bhagat, MD, Venkatraman Seshan, Sean Clark-Garvey, Jasmine M. Zain, MD, Catherine S. Diefenbach, MD, Erin McCormick, Meaghan Conroy, Meghan Crook, Bachir Alobeid, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4151.

https://doi.org/10.1182/blood.V116.21.4151.4151

Published: 2010

NARROW

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Phase I/Ib Study of the Novel Immunotoxin MT-3724 in Relapsed/Refractory Non-Hodgkin's B-Cell Lymphoma (NHL)

Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.

Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only